Scrutinizers Report of 21st Annual General Meeting
AKUMS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Akums Drugs and Pharmaceuticals held its 21st AGM on July 18, 2025 via video conferencing, where all five resolutions were passed with overwhelming majority. Around 90.36% of outstanding shares participated through remote e-voting. The ordinary resolution to adopt audited standalone and consolidated financial statements for FY ended March 31, 2025 was approved with 99.9999% votes in favour (142.22 crore shares). Re-appointment of Mr. Sanjeev Jain (DIN: 00323433) as a Director, who retires by rotation, was approved with 99.65% in favour (14.17 crore shares) against just 0.35% dissent. Appointment of Secretarial Auditors for FY 2025-26 to FY 2029-30 was approved with 99.68% votes in favour.
All resolutions cleared comfortably with negligible opposition (highest dissent at 0.35% for Sanjeev Jain's re-appointment), reflecting strong shareholder confidence. The appointment of Mr. Anil Kumar Arvindlal Amin as Independent Director and five-year Secretarial Auditors strengthen board oversight, though these are routine governance items unlikely to materially move the stock price.